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To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour
activity, we conducted a combination phase I study in advanced non-small-cell lung cancer (NSCLC). Patients received nedaplatin
(60–100mgm
2 given intravenously over 90min) on day 1, and gemcitabine (800–1000mgm
2 given intravenously over 30min)
on days 1, 8, every 3 weeks. In total, 20 patients with locally advanced or metastatic NSCLC who received no prior chemotherapy or
one previous chemotherapy regimen were enrolled. The most frequent toxicities were neutropenia and thrombocytopenia;
nonhaematological toxicities were generally mild. Three out of six patients experienced dose-limiting toxicities (neutropenia,
thrombocytopenia and delayed anaemia) at dose level 4, 100mgm
2 nedaplatin with 1000mgm
2 gemcitabine, which was regarded
as the MTD. There were three partial responses, for an overall response rate of 16.7%. The median survival time and 1-year survival
rate were 9.1 months and 34.1%, respectively. This combination is well tolerated and active for advanced NSCLC. The
recommended dose is 80mgm
2 nedaplatin with 1000mgm
2 gemcitabine. This combination chemotherapy warrants a phase II
study and further evaluation in prospective randomised trials with cisplatin- or carboplatin-based combinations as first-line
chemotherapy for advanced NSCLC.
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Based on the results of a meta-analysis (Non-Small Cell Lung
Cancer Collaborative Group, 1995), cisplatin-based chemotherapy
is considered the best available therapy for patients with locally
advanced or metastatic non-small-cell lung cancer (NSCLC).
Although several new agents with novel mechanisms and signi-
ficant activity against NSCLC have been introduced, such as taxanes,
gemcitabine and vinorelbine, any of these agents used in combina-
tion with a platinum agent provide equivalent survival improvement
(Kelly et al, 2001; Schiller et al, 2002; Fossella et al,2 0 0 3 ) .T h e
prognosis of advanced NSCLC patients who receive cisplatin-based
chemotherapy is still poor, and the renal and gastrointestinal
toxicities caused by cisplatin often limit its clinical use. Therefore,
development of different treatment strategies is necessary.
Nedaplatin is a second-generation platinum derivative that has
shown equivalent antitumour activity and lower toxicity – less
nausea, and lower nephrotoxicity and neurotoxicity – than
cisplatin (Kameyama et al, 1990; Ota et al, 1992). A phase I study
demonstrated the maximum tolerated dose (MTD) and the
recommended dose (RD) for phase II studies of nedaplatin was
120 and 100mgm
2, respectively, and the dose-limiting toxicity
(DLT) was thrombocytopenia (Ota et al, 1992). Two independent
phase II studies of nedaplatin for NSCLC showed response rates of
14.7 and 20.5%, respectively, and 16.7 and 12.5% with the patients
who had received chemotherapy previously (Fukuda et al, 1990;
Furuse et al, 1992a). Based on these promising results, a
randomised study of nedaplatin–vindesine vs cisplatin–vindesine
was conducted for previously untreated NSCLC patients in Japan
and indicated that nedaplatin-based chemotherapy yielded similar
response rates and overall survival (Furuse et al, 1992b).
Leucopenia, renal toxicities and gastrointestinal toxicities were
more frequent in the cisplatin–vindesine arm, while thrombocy-
topenia was more frequent in the nedaplatin–vindesine arm.
Gemcitabine, an analogue of deoxycytidine, is a pyrimidine
antimetabolite, that shows a reproducible response rates of 420%
with a median survival time of 9 months, offering a quality of life
benefit in comparison with best supportive care (Abratt et al, 1994;
Anderson et al, 1994; Gatzemeier et al, 1996; Anderson et al, 2000).
The main toxicity of gemcitabine is mild-to-moderate myelosup-
pression. The combination of gemcitabine and cisplatin showed
synergistic effects in preclinical studies because gemcitabine
inhibited the repair of DNA damage caused by cisplatin (Bergman
et al, 1996), and achieved high response rates along with
improvements in median survival time in clinical setting (Sandler
et al, 2000; Schiller et al, 2002; Alberola et al, 2003).
Recently, carboplatin has attracted attention ahead of nedaplatin
because it has similar activity to cisplatin with fewer nonhaema-
tological toxicities. The available data suggest that carboplatin–
paclitaxel or carboplatin–gemcitabine should be considered
among standard regimen for advanced NSCLC (Kelly et al, 2001;
Grigorescu et al, 2002; Rudd et al, 2002; Schiller et al, 2002).
It seems that nedaplatin has activity and toxicity profiles similar
to those of carboplatin, although no randomised trial has not been
done to allow direct comparison (Fukuda et al, 1990; Furuse et al,
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l1992a; Ota et al, 1992). Moreover, Matsumoto et al (2001)
demonstrated that the combination of nedaplatin and gemcitabine
resulted in enhanced inhibition of tumour growth in vivo and the
antitumour efficacy of the combination was superior to that of
cisplatin–gemcitabine or carboplatin–gemcitabine. Based on the
results of a preclinical study, we designed the present phase I study
of the efficacy of the combination of nedaplatin and gemcitabine
for advanced NSCLC. The purpose of this study was to establish
the toxicities and MTD of this combination, to determine the RD
for phase II studies, and to observe their antitumour activity.
PATIENTS AND METHODS
Patient eligibility
Patients with histologic or cytologic confirmation of locally
advanced or metastatic NSCLC who received either no prior
chemotherapy or one previous chemotherapy regimen were
eligible. The eligibility criteria were as follows; (1) measurable
lesions; (2) age p75 years; (3) Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0–1; (4) adequate organ
function (a white blood count (WBC) X4000ml
1, a neutrophil
count X2000ml
1, a platelet count X100000ml
1, a haemoglobin
count X9.5gdl
1, serum total bilirubin p1.5mgdl
1, serum
transaminase p2 upper normal limits, a serum creatinine p
upper normal limits, blood urea nitrogen (BUN) p25mgdl
1,
PaO2 X60mmHg or SpO2 X90%]; and (5) normal electrocardio-
gram (ECG). At least 4 weeks must have passed after the
completion of previous therapy and the patients had to have
recovered from the toxic effects of previous therapy. The exclusion
criteria consisted of pulmonary fibrosis or interstitial pneumonitis
with symptoms or apparent abnormalities on chest X-ray, massive
pleural effusion or ascites, acute inflammation, pregnancy,
lactation, symptomatic brain metastases, active concurrent malig-
nancies, severe drug allergies, severe heart disease, cerebrovascular
disease, uncontrollable diabetes mellitus or hypertension, severe
infection, active peptic ulcer, ileus, paralysis intestinal, diarrhoea
and jaundice. This study was performed at Kinki University
School of Medicine and was approved by the Institutional
Review Board. Written informed consent was obtained from all
patients. This study was conducted in accordance with Declaration
of Helsinki.
Pretreatment and follow-up studies
Prior to entry, a complete history was taken and physical
examination including age, height, weight, performance status,
histological diagnosis, tumour stage, contents of previous treat-
ment and presence of a complication was performed. The
pretreatment laboratory investigations included a complete blood
cell count, differential WBC count, platelet count, serum electro-
lytes, total protein, albumin, total bilirubin, transaminase, alkaline
phosphatase, lactate dehydrogenase, BUN, creatinine, creatinine
clearance and urinalysis. After the initiation of therapy, a complete
blood cell count with a differential WBC count was performed at
least twice a week. Blood chemistry profiles and chest X-ray films
were obtained weekly. The lesion measurements were performed
during at least every second course. Toxicities were evaluated
according to the National Cancer Institute Common Toxicity
Criteria (NCI-CTC) version 2 and tumour responses were assessed
using the Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines (Therasse et al, 2000). Time to progression was
measured from the date of registration to the date of first
progression or death from any cause. Survival time was also
measured from the date of registration to the date of death or latest
follow-up, and was calculated using the Kaplan–Meier method
(Kaplan and Meier, 1958).
Drug administration and dose escalation
The treatment schedule included nedaplatin, diluted with 500ml of
normal saline, given intravenously over 90min on day 1, and
gemcitabine with 100ml of normal saline, given intravenously over
30min after the completion of nedaplatin infusion on days 1 and 8,
every 3 weeks. All patients were allowed to receive antiemetics with
dexamethasone and granisetron, and post-therapy hydration with
1000ml of normal saline. Granulocyte colony-stimulating factor
(G-CSF) prophylaxis was not administered. Doses of gemcitabine
on day 8 were given if the WBC count was 42000ml
1 and/or the
platelet count was 4750000ml
1, and/or allergic reaction, fever,
elevation of transaminase and pneumonitis were less than grade 2,
and/or the other nonhaematological toxicities were less than grade
3. The subsequent courses were withheld until the toxic levels
returned to those specified in the eligibility criteria. The doses of
both drugs were decreased by one dose level if DLTs occurred. In
the case of the initial dose level, the doses of nedaplatin and
gemcitabine were reduced by 20 and 200mgm
2, respectively.
Dose escalations were performed as listed in Table 1. Intrapatient
dose escalation was not allowed. At least three patients were treated
at each dose level, and three additional patients were entered at the
same dose level if DLT was observed in one of the first three
patients. The MTD was defined as the dose level at which more
than two of three patients, or three of six patients experienced DLT.
The definition of DLT was as follows: (1) grade 4 leukopenia, (2)
grade 4 neutropenia for more than 4 days, (3) thrombocytopenia
o20000ml
1, (4) grade 3 febrile neutropenia, (5) grade 3 nonhae-
matologic toxicity except for nausea/vomiting, (6) delay of admi-
nistration of gemcitabine on day 8 over a week for toxicities.
RESULTS
Between August 2001 and February 2003, 20 patients were enrolled
in this study. The total and the median number of courses were 56
and 3 (range 1–6), respectively. The patients’ characteristics are
shown in Table 2. The majority of patients had a PS of 1. There
Table 1 Dose-escalation schema
Nedaplatin dose Gemcitabine dose No. of patients
Dose level (mgm
2)( m g m
2) (courses)
1 60 800 3 (8)
2 80 800 3 (10)
3 80 1000 8 (18)
4 100 1000 6 (20)
Table 2 Patients’ characteristics
No. of patients 20
Age, years Median 63.5
Range 36–74
Sex Male/female 17/3
Performance status 0/1 5/15
Histology Adeno/squamous 13/7
Stage IIIB/IV 4/16
Prior therapy None 5
Surgery 5
Radiation 6
Chemotherapy 14
CDDP-based 3
CBDCA-based 4
Nonplatinum 4
UFT 2
Gefitinin 1
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lwere five previously untreated patients (level 3, two patients; level
4, three patients) and 15 (75%) previously treated patients. Of the
previously treated patients, five had received prior surgery, five
had prior radiotherapy, and 14 had prior chemotherapy. Seven had
received platinum-based chemotherapy (cisplatin, three patients;
carboplatin, four patients), and four a nonplatinum regimen.
Responses to previous chemotherapy included partial response in
five patients, stable disease in seven, progressive disease in one,
and not evaluable in one. The median interval from previous
treatment was 16 weeks (range 4–92.5 weeks). Out of 20 patients,
18 were assessable for toxicity and response. Two patients at level 3
were excluded from the toxicity and response evaluation because
they had refused this study after registration.
Toxicities
The haematological and nonhaematological toxicities observed
during the first course are shown in Tables 3 and 4, respectively.
The most frequent toxicities observed in the first cycle were
neutropenia and thrombocytopenia (Table 3). One-third of the
patients had grade 3 thrombocytopenia, and one patient received a
platelet transfusion during the first course. Three patients had
grade 4 neutropenia for no longer than 4 days. The nadir for
neutropenia and thrombocytopenia occurred on day 15 (median,
range 5–18), and on day 15 (median, range 8–18), respectively.
Nonhaematological toxicities generally were mild because none of
the patients had experienced more than grade 3 in the first course
(Table 4). The major toxicities following all courses are listed in
Table 5. Grade 3 thrombocytopenia occurred in 16 out of 56
courses, and three patients received platelet transfusion (one
patient at level 1, one at level 3 and one at level 4). However, no
patient had haemorrhagic complications. The most frequent
nonhaematological toxicities were elevation of transaminase
activity, nausea and appetite loss, but all were mild. One previously
untreated patient at level 3 experienced grade 3 pneumonitis after
the fifth course, probably induced by this treatment, and the
patient’s condition improved after the administration of steroid.
There was no treatment-related death. One of the 18 patients at
level 4 underwent dose reduction after the first course due to
neutropenia, and two patients at level 3 did not receive
gemcitabine on day 8 because they had neutropenia, thrombocy-
topenia and high transaminase activity. Delays in the commence-
ment of subsequent courses occurred in 11 courses, and the
median length of the delay before starting the subsequent course
was 21 days (21–35 days).
MTD and DLTs
At levels 1 and 2, none of the patients had developed a DLT.
Haematological and nonhaematological toxicities were generally
mild at these levels, although one patient had grade 3 thrombo-
cytopenia at level 1. At level 3, two of six assessable patients had
developed DLTs. Both could not receive their scheduled dose of
gemcitabine on day 8 because they had neutropenia, thrombocy-
topenia and high transaminase activity. At level 4, three of six
patients had developed DLTs. One patient received G-CSF for
neutropenia, not lasting more than 4 days, which was considered
as the DLT. Another patient required a platelet infusion because of
thrombocytopenia o20000ml
1. The third patient could not
receive the second course due to the delayed anaemia, also
considered as DLT. Therefore, dose level 4, 100mgm
2 nedaplatin
with 1000mgm
2 gemcitabine was regarded as the MTD. The
recommended dose level for further phase II study was determined
to be 80mgm
2 nedaplatin with 1000mgm
2 gemcitabine (dose
level 3 in this study).
Response and survival
There were three partial responses, for an overall response rate of
16.7%. As for squamous cell carcinoma, only one out of seven
Table 3 Haematological toxicity following first course of nedaplatin and gemcitabine
WBC grade ANC grade plt grade Hb grade
Dose level No. of patients 01234012340 1 2 3 4 01234
1 3 0 2 1 0 0 0 1 2 0 00111002100
2 3 1 0 2 0 0 1 0 1 1 00300001200
3 6 1 1 2 1 0 2 0 0 3 11212033000
4 6 1 0 3 2 0 0 0 3 1 20213003300
Table 4 Nonhaematological toxicity following first course of nedaplatin and gemcitabine
Nausea grade Vomiting grade Fatigue grade Transaminase grade
Dose level No. of patients 01234012340 1 2 3 4 0 1 2 3 4
1 3 3000030000 2 1 0 0 0 3 0 0 0 0
2 3 1110030000 1 2 0 0 0 1 2 0 0 0
3 6 2310051000 4 2 0 0 0 3 1 2 0 0
4 6 2220060000 6 0 0 0 0 1 5 0 0 0
Infection grade Fever grade Appetite loss grade Constipation grade
Dose level No. of patients 01234012340 1 2 3 4 0 1 2 3 4
1 3 3000030000 3 0 0 0 0 3 0 0 0 0
2 3 2010021000 1 2 0 0 0 3 0 0 0 0
3 6 6000060000 2 4 0 0 0 4 2 0 0 0
4 6 4020060000 2 4 0 0 0 4 2 0 0 0
A phase I study of nedaplatin and gemcitabine
T Kurata et al
2094
British Journal of Cancer (2004) 90(11), 2092–2096 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lpatients had a partial response. The median progression-free
survival time was 5.1 months. The median survival time and 1-year
survival rate were 9.1 months and 34.1%, respectively. Out of 15
patients who had received prior treatment, two (13.3%) achieved a
partial response, and there was no clear relationship between
responses to previous treatment and responses to this regimen. For
previously treated patients, the median survival time and 1-year
survival rate were 9.2 months and 40.3%, respectively. Among five
previously untreated patients, one (20%) achieved a partial
response and the median survival time and 1-year survival rate
were 12.0 months and 50.0%, respectively.
DISCUSSION
Many recent randomised clinical trials have shown that the
combinations of cisplatin with one of the new agents, such as
gemcitabine, taxanes or vinorelbine, is the standard therapy for
patients with locally advanced or metastatic NSCLC (Non-Small
Cell Lung Cancer Collaborative Group, 1995; Kelly et al, 2001;
Schiller et al, 2002; Fossella et al, 2003). As it is known that
cisplatin strongly promotes nephrotoxicity, neurotoxicity and
gastrointestinal toxicity, second-generation platinum-containing
compounds including carboplatin have attracted attention. Based
on several randomised trials that have shown that the combination
of carboplatin with paclitaxel produces similar response rates and
overall survival with a more favourable toxicity profile than the
combination of cisplatin with new agents (Kelly et al, 2001;
Scagliotti et al, 2002; Schiller et al, 2002), combined therapy of
carboplatin and paclitaxel is considered to be a standard therapy.
More recently, the combination of carboplatin with gemcitabine
has become attractive as a therapy for advanced NSCLC. Some
randomised studies have indicated that carboplatin–gemcitabine
regimen offers equivalent median survival compared with
cisplatin–gemcitabine or mitomycin–vinblastine–cisplatin /mito-
mycin–ifosfamide–cisplatin (Danson et al, 2003; Zatloukal et al,
2003), and results in significant improvements in overall survival
over those for gemcitabine alone or the older cisplatin-containing
regimens (Grigorescu et al, 2002; Rudd et al, 2002; Sederholm,
2002). However, neutropenia and thrombocytopenia were more
common in carboplatin–gemcitabine regimens than others;
thrombocytopenia was particularly common.
Like carboplatin, nedaplatin is also a second-generation
platinum derivative that appears to have a similar mechanism
and toxicity profile to carboplatin, although direct comparison has
not been performed. Moreover, in vivo study suggested that
nedaplatin–gemcitabine resulted in more enhanced inhibition of
tumour growth than cisplatin–gemcitabine or carboplatin–
gemcitabine. These results prompted us to investigate nedapla-
tin-based combinations and to conduct this phase I study.
With respect to toxicities, the most frequent toxicities were
haematological toxicities, especially neutropenia and thrombocy-
topenia. Eight of 18 patients (44.4%) developed more than grade 3
neutropenia after the first courses, and after 16 out of 56 (28.6%)
courses overall. On the other hand, six out of 16 patients (37.5%)
developed grade 3 thrombocytopenia after the first courses, and
after 16 out of 56 courses (37.5%) overall. However, patients
required platelet transfusions during only three courses. In
addition, one previously untreated patient developed drug-related
pneumonitis, which improved with the administration of steroid,
at level 3 after the fifth course.
Overall, the toxicities of the combination of nedaplatin with
gemcitabine were generally mild and this combination chemother-
apy is both well tolerated and active against advanced NSCLC.
The overall response rate of 16.7%, the median survival time of
9.1 months, and 1-year survival rate of 34.1% in this study were
quite acceptable because most patients had been given prior
chemotherapy. As evaluation of antitumour activity was not a
primary objective, and our patient population was small and
heterogeneous, we are unable to draw definitive conclusions about
the activity of this regimen. Currently, it is still controversial
whether novel platinum compounds such as carboplatin and
nedaplatin could replace cisplatin for the treatment of advanced
NSCLC. However, when not only antitumour activity but also
palliation are the main goals of treatment, these new platinum
compounds might play a useful role because of their favourable
toxicity profile. Therefore, nedaplatin–gemcitabine warrants a
phase II study, and further evaluation in prospective randomised
trials with cisplatin- or carboplatin-based combinations as a first-
line chemotherapy for advanced NSCLC in order to investigate
whether nedaplatin could replace cisplatin or carboplatin.
In conclusion, the combination of nedaplatin with gemcitabine
is well tolerated and active for advanced NSCLC. The MTD and
recommended dose level are 100mgm
2 nedaplatin with 1000mgm
2
gemcitabine and 80mgm
2 nedaplatin with 1000mgm
2 gemci-
tabine, respectively.
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